2012 EDUCATIONAL BOOK - American Society of Clinical Oncology

New Looks and Challenges for Cooperative Groups
The New National Cancer Institute National Clinical Trials Network
Stephen S. Grubbs .................................................................................... 146
Successful Integration of Cooperative Groups: The Origin of the Children’s Oncology Group
Gregory H. Reaman. .................................................................................. 149
Overcoming Disparities in Clinical Trial Accrual among African Americans
A Critical Review of the Enrollment of Black Patients in Cancer Clinical Trials
Deliya R. Banda, Diane St. Germain, Worta McCaskill-Stevens, Jean G. Ford, and Sandra M. Swain ................ 153
Developmental Therapeutics
Antibody Conjugates: Targeted Therapy Meets Chemotherapy in One Drug
Trastuzumab Emtansine (T-DM1): Hitching a Ride on a Therapeutic Antibody
Howard A. Burris III .................................................................................. 159
Targeting CD30 in Hodgkin Lymphoma: Antibody-Drug Conjugates Make a Difference
Catherine S. M. Diefenbach and John P. Leonard .......................................................... 162
Early Drug Development: Casting a Wide Net versus Preselecting a Narrow Audience
Approval of New Agents after Phase II Trials
Bruce Chabner ................................................................................... eArticle
Drug Development in the Era of Personalized Oncology: From Population-Based Trials to Enrichment and
Prescreening Strategies
Rodrigo Dienstmann, Jordi Rodon, and Josep Tabernero. .................................................... 168
Immunotherapy with the T-cell Checkpoint Antibodies: Implications for the Practitioner
Practical Management of Immune-Related Adverse Events from Immune Checkpoint Protein Antibodies for
the Oncologist
Jeffrey S. Weber. ..................................................................................... 174
Targeting Critical Molecular Aberrations Early in the Course of Solid Tumors: Is It about Time?
Treatment of Chronic Myelogenous Leukemia as a Paradigm for Solid Tumors: How Targeted Agents in Newly Diagnosed
Disease Transformed Outcomes
Jason R. Westin, Hagop Kantarjian, and Razelle Kurzrock ................................................... 179
Targeting Molecular Aberrations in Breast Cancer: Is It about Time?
Laura Esserman, Christopher Benz, and Angela DeMichele .................................................. 186
Ethics
Ethical Challenges of Health Care
Core Elements of the Patient Protection and Affordable Care Act and Their Relevance to the Delivery of
High-Quality Cancer Care
Beverly Moy, Amy P. Abernethy, and Jeffrey M. Peppercorn .............................................. eArticle
International Variation in Understanding Oncologists’ Professional Duties toward Patients, Families, and Themselves
A Balanced Approach to Physician Responsibilities: Oncologists’ Duties toward Themselves
Amy P. Abernethy ................................................................................. eArticle
Are Oncologists Accountable Only to Patients or Also to Their Families? An International Perspective
Antonella Surbone and Lea Baider ................................................................... eArticle
The Oncologist’s Duty to Provide Hope: Fact or Fiction?
Simon Wein ...................................................................................... eArticle
Medical Errors in Cancer Care: Prevention, Disclosure, and Patient and Family Member Responses
Oncologists’ Difficulties in Facing and Disclosing Medical Errors: Suggestions for the Clinic
Antonella Surbone. ................................................................................ eArticle
Preventing Errors in Oncology: Perspective of a Physician Who Is Also a Cancer Patient
Itzhak Brook ..................................................................................... eArticle